drugset / Trial / NCT02824042
Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole
NaSingle-groupOpen-labelTreatment
Summary
Characterize the safety, tolerability, ECG effects, pharmacokinetics and immunogenicity of anetumab ravtansine given as single agent and after inhibition of CYP3A4 and P-gp by concomitant administration of itraconazole in subjects with mesothelin-expressing advanced solid cancers
Timeline
- Start
- 2016-09-07
- Primary completion
- 2018-06-27
- Completion
- 2019-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anetumab Ravtansine | Monoclonal antibody | 0.6 mg/kg | Intravenous |
| Subject | Anetumab Ravtansine | Monoclonal antibody | 6.5 mg/kg | Intravenous |
| Subject | Itraconazole | Small molecule | 200 mg | Oral |
Indications
No indication recorded.